Sign inSign up
Sign upSign in

Research · Trials

The clinical trials,
by compound.

Every registered trial we track for our compounds, pulled from ClinicalTrials.gov. Filter by compound, status, and phase — or download the full directory as data.

378 tracked trials · 178 active ·60 with posted results · Source: ClinicalTrials.gov API v2 · Updated 2026-10-15 · Public domain (U.S. Government work)

GLP-1 trials dataset →Peptide trials dataset →

378 of 378 trials shown

TrialCompoundsPhaseStatusEnroll.Start
Tirzepatide for the Treatment of Cannabis Use DisorderNCT07265752 · Brigham and Women's HospitalTirzepatidePhase 2Not yet recruiting●Now tracking62027-03-01
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese PatientsNCT07847515 · Nanjing First Hospital, Nanjing Medical UniversityTirzepatide—Not yet recruiting●Now tracking802027-02-01
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant AccessNCT07858331 · Kristin ClemensSemaglutidePhase 4Not yet recruiting●Now tracking8802027-01-01
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNCT07787936 · Miedziowe Centrum Zdrowia SALiraglutideDulaglutide—Not yet recruiting●Now tracking1502027-01-01
Impact of BPC-157 on Recovery Following Rotator Cuff Repair SurgeryNCT07803250 · University of ArkansasBPC-157Phase 1Not yet recruiting●Now tracking302027-01-01
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838 · UNC Lineberger Comprehensive Cancer CenterTirzepatidePhase 2Not yet recruiting●Now tracking402027-01
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861 · Eli Lilly and CompanyOrforglipronPhase 3Not yet recruiting●Now tracking1922026-12
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · Boehringer IngelheimSemaglutideTirzepatidePhase 3Not yet recruiting●Now tracking3502026-11-07
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066 · AmgenSemaglutidePhase 3Not yet recruiting●Now tracking13002026-11-02
Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNCT07832084 · Jing LuoSemaglutideTirzepatidePhase 4Not yet recruiting●Now tracking602026-11-01
Metabolic Surgery for Atrial Fibrillation EliminationNCT07027969 · Ali AminianLiraglutideDulaglutidePhase 4Not yet recruiting1002026-11-01
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332 · Massachusetts General HospitalOrforglipronPhase 4Not yet recruiting●Now tracking602026-11-01
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)NCT07099742 · Dr. Md. Alimur RezaTirzepatide—Not yet recruiting●Now tracking3642026-11
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNCT06977438 · University of MinnesotaSemaglutidePhase 4Not yet recruiting●Now tracking10202026-10-15
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationNCT07868354 · Novo Nordisk A/STirzepatidePhase 1Not yet recruiting●Now tracking602026-10-08
FutureShape FamilyNCT07872904 · Signe TorekovSemaglutidePhase 4Not yet recruiting●Now tracking4002026-10-01
Danish Trial of Weight Loss to Reduce Atrial Fibrillation ProgressionNCT07816744 · Axel BrandesSemaglutide—Not yet recruiting●Now tracking4802026-10-01
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500 · PfizerTirzepatidePhase 3Not yet recruiting●Now tracking6602026-10-01
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNCT07846865 · Woolcock Institute of Medical ResearchTirzepatidePhase 2/Phase 3Not yet recruiting●Now tracking2562026-10-01
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderNCT07825857 · University of Texas Southwestern Medical CenterTirzepatidePhase 2Not yet recruiting●Now tracking2282026-10-01
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationNCT07808879 · Peking Union Medical College HospitalExenatide—Recruiting●Now tracking202026-10-01
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNCT07739537 · Massachusetts General HospitalOrforglipronPhase 4Not yet recruiting●Now tracking1002026-10-01
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · General Committee of Teaching Hospitals and Institutes, EgyptSemaglutidePhase 4Not yet recruiting●Now tracking1042026-10
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189 · General Committee of Teaching Hospitals and Institutes, EgyptSemaglutidePhase 4Not yet recruiting●Now tracking1002026-10
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · General Committee of Teaching Hospitals and Institutes, EgyptSemaglutidePhase 4Not yet recruiting●Now tracking1002026-10
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137 · General Committee of Teaching Hospitals and Institutes, EgyptSemaglutidePhase 4Not yet recruiting●Now tracking1002026-10
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · General Committee of Teaching Hospitals and Institutes, EgyptSemaglutidePhase 4Not yet recruiting●Now tracking1002026-10
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891 · ProGen. Co., Ltd.DulaglutidePhase 2Not yet recruiting602026-10
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNCT07855133 · Novo Nordisk A/SSemaglutidePhase 1Not yet recruiting●Now tracking602026-09-30
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting●Status change1502026-09-25
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNCT07846956 · Istanbul Saglik Bilimleri UniversityTirzepatide—Not yet recruiting●Now tracking282026-09-21
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792 · yifang zhuTirzepatidePhase 2/Phase 3Not yet recruiting●Now tracking7262026-09-20
A Study of BGM0504 in Early T2DM With ObesityNCT07743983 · BrightGene Bio-Medical Technology Co., Ltd.SemaglutidePhase 3Recruiting●Now tracking3722026-09-17
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumNCT06073184 · GynOncTrialsSemaglutidePhase 2Recruiting●Now tracking712026-09-17
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · Novo Nordisk A/SCagrilintidePhase 3Recruiting●Status change2102026-09-16
Tirzepatide for Treatment of CCCANCT07734870 · Johns Hopkins UniversityTirzepatidePhase 2Recruiting●Now tracking202026-09-15
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744 · Eli Lilly and CompanyTirzepatidePhase 1Recruiting●Status change182026-09-11
IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019 · Innovent Biologics (Suzhou) Co. Ltd.OrforglipronPhase 1Recruiting●Status change1042026-09-07
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · Eli Lilly and CompanyDulaglutideOrforglipronPhase 3Not yet recruiting1702026-09
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal DiseaseNCT07478653 · Oelisoa AndriankajaSemaglutide—Recruiting●Now tracking502026-08-31
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightNCT07842640 · Ascletis Pharma (China) Co., LimitedTirzepatidePhase 1Recruiting●Now tracking842026-08-27
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 · Novo Nordisk A/SCagrilintidePhase 2Withdrawn02026-08-27
A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating SpectrumNCT07870538 · Universitaire Ziekenhuizen KU LeuvenSemaglutidePhase 4Recruiting●Now tracking962026-08-26
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting●Status change20012026-08-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · Novo Nordisk A/SCagrilintidePhase 3Recruiting●Status change802026-08-04
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504 · Novo Nordisk A/SCagrilintidePhase 3Recruiting●Status change2852026-08-04
Imaging in Semaglutide StudyNCT07695454 · The Cleveland ClinicSemaglutide—Recruiting●Now tracking102026-07-30
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting●Status change1302026-07-15
Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesNCT07835360 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranTirzepatide—Recruiting●Now tracking2002026-07-10
Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative StudyNCT07866183 · National Medical Research Center for Therapy and Preventive MedicineTirzepatide—Recruiting●Now tracking1202026-06-29
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · Novo Nordisk A/SSemaglutidePhase 2Recruiting●Now tracking3002026-06-22
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · Novo Nordisk A/SCagrilintidePhase 3Withdrawn02026-06-22
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsNCT07702461 · Ohio State UniversityLiraglutideDulaglutideExenatide—Recruiting●Now tracking3002026-06-12
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisNCT06726577 · Talengen Institute of Life Sciences, Shenzhen, P.R. China.LiraglutidePhase 1/Phase 2Recruiting602026-06-04
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesNCT07858864 · Istanbul Saglik Bilimleri UniversitySemaglutideTirzepatide—Recruiting●Now tracking422026-05-30
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1142026-05-29
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910 · Regeneron PharmaceuticalsTirzepatidePhase 2Recruiting●Now tracking2042026-05-22
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · Novo Nordisk A/SCagrilintidePhase 3Recruiting25002026-05-21
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)NCT07559500 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)TirzepatidePhase 1Recruiting●Now tracking1762026-05-20
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 · Novo Nordisk A/SCagrilintidePhase 1Completed●Status change502026-05-20
Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyNCT06948214 · Lumos PharmaMK-677Phase 3Recruiting1502026-05-20
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 · Novo Nordisk A/SCagrilintidePhase 1Recruiting2342026-05-18
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial InfarctionNCT07586865 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Not yet recruiting1892026-05-18
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · The Fourth Affiliated Hospital of Zhejiang University School of MedicineLiraglutidePhase 4Not yet recruiting1202026-05-01
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · First Affiliated Hospital of Wannan Medical CollegeDulaglutidePhase 4Not yet recruiting4682026-05
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1202026-04-30
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisNCT07497399 · Johns Hopkins UniversityExenatidePhase 2Recruiting1202026-04-28
Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · UNC Lineberger Comprehensive Cancer CenterTirzepatideEARLY_Phase 1Recruiting●Now tracking202026-04-27
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1002026-04-10
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878 · Baylor Research InstituteSemaglutidePhase 4Enrolling by invitation●Now tracking642026-04-08
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · Mayo ClinicTirzepatidePhase 4Recruiting●Now tracking402026-04-08
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334 · University of FloridaLiraglutideOrforglipronPhase 2Recruiting202026-04-07
A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846 · Alnylam PharmaceuticalsTirzepatidePhase 1/Phase 2Recruiting●Now tracking1562026-03-02
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal TransplantationNCT07678073 · University of GaziantepMOTS-c—Recruiting682026-03-01
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKDNCT07187830 · University of AlbertaSemaglutide—Recruiting●Now tracking522026-02-23
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic OutcomesNCT07424430 · LMC Diabetes & Endocrinology Ltd.Semaglutide—Completed●Now tracking33922026-02-20
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 · Hudson BiotechRetatrutidePhase 2Recruiting3002026-02-15
The Evira Study: Additional Support During Obesity TreatmentNCT06836284 · Karolinska InstitutetLiraglutide—Recruiting402026-02-13
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1002026-02-09
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363 · Hudson BiotechTB-500Thymosin Beta-4Phase 1/Phase 2Recruiting802026-02-05
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631 · Brigham and Women's HospitalDulaglutide—Completed3000002026-02-03
BPC 157 for Acute Hamstring Muscle Strain RepairNCT07437547 · Hudson BiotechBPC-157Phase 2Recruiting1202026-02-02
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)NCT07481734 · Hudson BiotechTesamorelinPhase 2Recruiting1202026-02-02
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityNCT07505745 · Hudson BiotechMOTS-cPhase 2Recruiting1202026-02-02
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618 · Brigham and Women's HospitalDulaglutide—Completed600002026-01-27
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting6002026-01-24
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495 · Brigham and Women's HospitalDulaglutide—Completed1200002026-01-20
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080 · The First Affiliated Hospital of Henan University of Science and TechnologyExenatideEARLY_Phase 1Recruiting92026-01-20
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · Novo Nordisk A/SCagrilintidePhase 3Recruiting4602026-01-08
Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139 · Indiana UniversityLiraglutide—Enrolling by invitation1250002026-01-01
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979 · KaileraSemaglutidePhase 3Active not recruiting●Now tracking12702025-12-30
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813 · Eli Lilly and CompanyDulaglutidePhase 1Completed●Status change202025-12-29
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041 · National University of SingaporeDulaglutidePhase 2/Phase 3Recruiting1302025-12-17
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNCT07276763 · Fudan UniversityDulaglutide—Not yet recruiting165092025-12-10
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting71402025-12-01
ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingNCT07871799 · Sheba Medical CenterSemaglutidePhase 2Completed●Now tracking312025-11-17
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting2502025-11-17
Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesNCT07834398 · Zagazig UniversityDulaglutidePhase 3Completed●Now tracking1502025-11-14
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816 · Novo Nordisk A/SLiraglutidePhase 1Recruiting712025-11-07
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting3302025-11-05
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting3002025-11-05
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting12052025-10-31
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111 · Zagazig UniversityDulaglutidePhase 3Completed●Now tracking1592025-10-18
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Eli Lilly and CompanyTirzepatideRetatrutidePhase 3Recruiting45002025-10-15
A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539 · Jiangsu Hansoh Pharmaceutical Co., Ltd.DulaglutidePhase 3Not yet recruiting5462025-09-30
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting10002025-09-30
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 · Novo Nordisk A/SCagrilintidePhase 1Active not recruiting●Now tracking802025-09-26
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)NCT07188545 · Ohio State UniversityDulaglutideExenatide—Active not recruiting232800002025-09-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting●Status change8002025-09-15
A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and RecoveryNCT07752381 · Parlay WellnessBPC-157—Completed●Now tracking402025-09-01
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286 · Ain Shams UniversityDulaglutidePhase 1/Phase 2Enrolling by invitation502025-08-04
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyNCT06903923 · University of VirginiaLiraglutidePhase 2Recruiting1202025-07-31
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVNCT06554717 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Recruiting1002025-07-10
Probiotics in Obese Patients Treated With SemaglutideNCT07847593 · Nordic Biotic Sp. z o.o.Semaglutide—Completed●Now tracking1022025-07-09
GLP-1s to Enhance Lasting Optimal WeightNCT06861439 · Wake Forest University Health SciencesTirzepatidePhase 4Active not recruiting●Now tracking402025-07-07
A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.SemaglutidePhase 3Active not recruiting●Now tracking1522025-07-04
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyNCT06759701 · M.D. Anderson Cancer CenterTirzepatideEARLY_Phase 1Recruiting●Now tracking302025-07-02
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting3502025-06-26
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting2902025-06-26
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829 · 4Moving BiotechLiraglutidePhase 2Active not recruiting●Status change1292025-06-17
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 · Novo Nordisk A/SCagrilintidePhase 1Recruiting●Now tracking1442025-06-12
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 · Eli Lilly and CompanyRetatrutidePhase 1Completed802025-06-06
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting6092025-06-03
Semaglutide for Helping Opioid RecoveryNCT06639464 · Brigham and Women's HospitalSemaglutidePhase 2Recruiting●Now tracking462025-06-02
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 · Eli Lilly and CompanySemaglutideRetatrutidePhase 1Active not recruiting●Status change952025-06-02
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting●Status change5862025-05-29
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · Fundación para la Investigación del Hospital Clínico de ValenciaDulaglutidePhase 4Completed●Status change922025-05-26
Tirzepatide vs Liraglutide in BoneNCT07094568 · National and Kapodistrian University of AthensLiraglutide—Recruiting722025-05-23
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting14002025-05-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting8002025-05-15
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminNCT07109700 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.DulaglutidePhase 2Recruiting2162025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting4872025-04-30
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting9742025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting4872025-04-30
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 DiabetesNCT06706284 · Marzieh SalehiSemaglutidePhase 4Recruiting●Now tracking502025-04-11
A Study of BGM0504 in Participants With ObesityNCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.TirzepatidePhase 2Completed●Now tracking962025-04-09
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475 · Eli Lilly and CompanySemaglutideTirzepatidePhase 2Recruiting●Now tracking2002025-03-28
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin ResistanceNCT06856291 · ETH ZurichSemaglutide—Completed●Now tracking402025-03-15
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting6432025-03-05
Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)NCT06854614 · The Cleveland ClinicTirzepatidePhase 4Active not recruiting●Now tracking1502025-03-01
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting4002025-02-10
Tirzepatide for Obesity and Meth Use DisorderNCT06745128 · University of Texas Southwestern Medical CenterTirzepatidePhase 2Completed●Now tracking352025-02-03
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 · Eli Lilly and CompanyRetatrutidePhase 1Completed302025-02-03
Study of Patients Being Treated With Anti-obesity MedicationNCT06790160 · Texas Tech UniversitySemaglutideTirzepatide—Active not recruiting●Now tracking1002025-01-31
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · Novo Nordisk A/SCagrilintidePhase 2Completed●Status change1422025-01-29
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · Eli Lilly and CompanyDulaglutidePhase 3Recruiting552025-01-10
Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshSemaglutidePhase 2/Phase 3Completed●Now tracking312025-01-01
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435 · MaryAnn BanerjiLiraglutideDulaglutidePhase 4Active not recruiting602024-12-21
Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantNCT05670379 · Vivani Medical, IncExenatidePhase 1Completed242024-12-20
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538 · Arrowhead PharmaceuticalsTirzepatidePhase 1/Phase 2Recruiting●Now tracking1802024-12-04
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 · Novo Nordisk A/SCagrilintidePhase 1Completed●Now tracking1782024-12-03
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 · Novo Nordisk A/SCagrilintidePhase 1Completed●Now tracking182024-12-02
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaNCT07370922 · Ain Shams UniversityDulaglutidePhase 2Completed802024-11-22
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)NCT06191848 · University of MelbourneTirzepatidePhase 4Active not recruiting●Now tracking3522024-11-19
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting1252024-11-18
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting1502024-11-18
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · Novo Nordisk A/SCagrilintidePhase 3Completed●Status change10232024-11-05
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting8002024-11-01
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929 · Brigham and Women's HospitalDulaglutide—Completed700002024-11-01
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking7122024-10-22
Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.NCT06888167 · Azienda Ospedaliero-Universitaria di ParmaExenatide—Recruiting402024-10-14
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryNCT06500143 · Ciusss de L'Est de l'Île de MontréalDulaglutide—Completed942024-10-09
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063 · Brigham and Women's HospitalDulaglutide—Completed8871322024-10-01
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718 · Brigham and Women's HospitalDulaglutide—Completed446712024-10-01
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515 · AstraZenecaExenatide—Recruiting240002024-09-30
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 · Eli Lilly and CompanyTirzepatidePhase 2Completed●Now tracking3672024-09-20
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · Eli Lilly and CompanyOrforglipronPhase 3Completed3762024-09-13
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectNCT06058585 · The George InstituteSemaglutidePhase 3Recruiting●Now tracking20002024-09-04
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNCT06449235 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersExenatidePhase 4Unknown●Status change9382024-09
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908 · Beni-Suef UniversityLiraglutidePhase 3Completed1832024-08-01
Exenatide For Reducing the Reinforcing Effects of CocaineNCT06252623 · Christopher D. VerricoExenatidePhase 1Withdrawn02024-08-01
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527 · The Cleveland ClinicDulaglutidePhase 4Completed692024-07-31
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · Beijing Dongfang Biotech Co., Ltd.DulaglutideExenatidePhase 3Active not recruiting6002024-07-17
Fibrosis Lessens After Metabolic SurgeryNCT06374875 · The Cleveland ClinicLiraglutidePhase 4Recruiting●Now tracking1202024-07-11
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsNCT06254014 · Beijing Dongfang Biotech Co., Ltd.ExenatidePhase 3Active not recruiting2702024-07-10
Risk Factors Affect Weight Loss Outcomes After Treatment.NCT06482411 · E-DA HospitalLiraglutide—Completed36022024-06-27
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 · Novo Nordisk A/SCagrilintidePhase 3Completed3002024-06-24
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980 · Eli Lilly and CompanyOrforglipronPhase 1Completed●Now tracking5332024-06-24
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical TrialNCT06050577 · Odense University HospitalSemaglutidePhase 2Active not recruiting●Now tracking642024-06-07
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting3002024-06-03
Diabetes Islet Preservation Immune TreatmentNCT02586831 · Camillo Ricordi and Jay SkylerExenatidePhase 1/Phase 2Withdrawn02024-06-01
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · Novo Nordisk A/SCagrilintidePhase 2Completed2702024-05-20
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761 · Novo Nordisk A/SCagrilintidePhase 1Completed1582024-05-06
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsNCT06370728 · Eli Lilly and CompanyOrforglipronPhase 1Completed●Now tracking302024-05-06
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting100002024-04-30
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · Eli Lilly and CompanyRetatrutidePhase 3Completed5372024-04-10
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641 · Novo Nordisk A/SLiraglutide—Completed3002024-04-08
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.DulaglutidePhase 3Completed6322024-04-08
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · Novo Nordisk A/SCagrilintidePhase 2Completed6262024-04-01
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219 · University of Sao Paulo General HospitalLiraglutidePhase 4Active not recruiting302024-03-30
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · Novo Nordisk A/SCagrilintidePhase 3Completed2742024-03-26
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 · Eli Lilly and CompanyRetatrutidePhase 1Completed852024-03-20
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461 · The University of Hong KongDulaglutidePhase 4Recruiting3722024-03-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 · Novo Nordisk A/SCagrilintidePhase 3Completed1892024-03-19
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting3202024-03-15
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · Novo Nordisk A/SCagrilintidePhase 1Completed342024-02-27
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 · Novo Nordisk A/SCagrilintidePhase 1Completed622024-02-23
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting12502024-02-21
A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092 · Novo Nordisk A/SCagrilintidePhase 1Completed1642024-02-15
A Study of HS-20094 in Patients With T2DMNCT06901648 · Jiangsu Hansoh Pharmaceutical Co., Ltd.DulaglutidePhase 2Completed2752024-02-06
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152 · University of ChicagoLiraglutideEARLY_Phase 1Suspended302024-01-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · Novo Nordisk A/SCagrilintidePhase 3Completed10242024-01-16
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMNCT06256419 · The Affiliated Hospital of Xuzhou Medical UniversityExenatide—Recruiting3002024-01-01
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141 · Göteborg UniversityLiraglutide—Completed1282023-12-20
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 · Novo Nordisk A/SCagrilintidePhase 3Completed8092023-11-27
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · Eli Lilly and CompanyTirzepatidePhase 2Recruiting●Now tracking14812023-11-17
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking5462023-11-10
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese SubjectsNCT06247748 · Beijing Dongfang Biotech Co., Ltd.ExenatidePhase 1Completed282023-10-19
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482 · Eli Lilly and CompanyOrforglipronPhase 1Completed102023-10-19
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · AdventHealth Translational Research InstituteDulaglutidePhase 2Recruiting●Status change472023-10-05
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · Eli Lilly and CompanyOrforglipronPhase 3Completed4012023-09-28
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · Novo Nordisk A/SCagrilintidePhase 3Completed27342023-09-27
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking16982023-09-22
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095 · Eli Lilly and CompanyOrforglipronPhase 1Completed●Now tracking242023-09-21
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094 · Cardenal Herrera UniversityDulaglutideExenatide—Recruiting2502023-09-15
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 · Eli Lilly and CompanyRetatrutidePhase 1Completed462023-09-12
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryNCT07374445 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutidePhase 4Completed1002023-09-01
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 · Eli Lilly and CompanyRetatrutidePhase 1Completed572023-08-29
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 · Novo Nordisk A/SCagrilintidePhase 3Completed3002023-08-15
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking5592023-08-09
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · Eli Lilly and CompanyRetatrutidePhase 3Completed4452023-08-01
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking2382023-07-31
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · Eli Lilly and CompanyRetatrutidePhase 2Completed1462023-07-20
A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 · Eli Lilly and CompanyRetatrutidePhase 1Completed852023-07-18
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 · Eli Lilly and CompanyRetatrutidePhase 1Completed432023-07-13
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138 · Eli Lilly and CompanyOrforglipronPhase 1Completed242023-07-13
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · Eli Lilly and CompanyRetatrutidePhase 3Completed●Status change11522023-07-11
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · Eli Lilly and CompanyRetatrutidePhase 3Completed23352023-07-10
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNCT05726227 · Novo Nordisk A/SSemaglutidePhase 3Active not recruiting●Now tracking2122023-07-07
Cathelicidin LL-37 Relation to Potentially Malignant LesionsNCT06219330 · Fayoum UniversityLL-37—Completed452023-07-01
Preoperative Weight Loss for Open Abdominal Wall ReconstructionNCT05925959 · Benjamin T. MillerLiraglutide—Recruiting2582023-06-19
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032 · Eli Lilly and CompanyOrforglipronPhase 1Completed292023-06-13
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · Eli Lilly and CompanyOrforglipronPhase 3Completed●Now tracking16132023-06-05
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting●Results posted31272023-06-05
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · Eli Lilly and CompanyRetatrutidePhase 3Completed●Status change19462023-05-30
Effects of GH and Lirglutide on AgRPNCT05681299 · Columbia UniversityLiraglutidePhase 4Recruiting402023-05-01
Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With DyslexiaNCT05832060 · Bambino Gesù Hospital and Research InstituteSelank—Unknown242023-05-01
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238 · Eli Lilly and CompanyOrforglipronPhase 1Completed522023-04-26
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesNCT05482789 · Maisa N. Feghali, MDExenatidePhase 4Recruiting132023-04-12
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2NCT05555589 · ReGenTree, LLCThymosin Beta-4Phase 3Recruiting702023-04-11
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 · Novo Nordisk A/SCagrilintidePhase 3Completed3312023-04-03
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting71012023-03-01
Clinical Study of 18F-Exendin-4 in InsulinomaNCT07340437 · Sichuan Provincial People's HospitalExenatide—Completed202023-02-01
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · Novo Nordisk A/SCagrilintidePhase 3Completed12002023-02-01
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249 · Novo Nordisk A/SLiraglutidePhase 4Completed5002023-01-19
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800 · The University of Texas Health Science Center, HoustonExenatidePhase 2Completed1402022-12-07
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039 · Eli Lilly and CompanyDulaglutidePhase 4Completed2822022-11-30
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 · Eli Lilly and CompanyRetatrutidePhase 1Completed292022-11-16
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting34002022-11-01
Semaglutide vs SitagliptinNCT05195944 · University Health Network, TorontoSemaglutidePhase 4Active not recruiting●Now tracking582022-10-26
A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 · Eli Lilly and CompanyRetatrutidePhase 1Completed322022-10-24
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · Eli Lilly and CompanyTirzepatidePhase 3Active not recruiting●Now tracking153742022-10-11
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutide—Completed●Status change3962022-10-08
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892 · Brigham and Women's HospitalLiraglutideDulaglutidePhase 4Recruiting60002022-09-26
The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseNCT05364684 · Massachusetts General HospitalMK-677Phase 2Completed122022-08-10
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126 · Eli Lilly and CompanyOrforglipronPhase 1Completed262022-08-01
Trifecta Research StudyNCT07717866 · Axial Therapeutic ResearchIpamorelin—Active not recruiting●Now tracking522022-08-01
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial InfarctionNCT05984134 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Completed902022-07-15
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · Eli Lilly and CompanyRetatrutidePhase 1Completed322022-07-08
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104 · Chinese University of Hong KongExenatidePhase 2Recruiting1102022-05-25
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089 · Eli Lilly and CompanyOrforglipronPhase 1Completed392022-05-17
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes MellitusNCT05662189 · Azienda Ospedaliero-Universitaria di ParmaExenatide—Recruiting702022-03-15
Adiponectin in Patients With Metabolic DisordersNCT07539584 · Moscow Regional Research and Clinical Institute (MONIKI)Liraglutide—Completed1302022-03-01
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 DiabetesNCT04307797 · Cambridge University Hospitals NHS Foundation TrustExenatidePhase 4Completed102022-01-18
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445 · Eli Lilly and CompanyOrforglipronPhase 1Completed●Now tracking622021-11-12
A Multiple Dose Study of LY3502970 in Healthy ParticipantsNCT05051566 · Eli Lilly and CompanyOrforglipronPhase 1Completed262021-09-16
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauExenatidePhase 4Completed422021-09-13
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · Brigham and Women's HospitalLiraglutideDulaglutideExenatide—Active not recruiting7814302021-08-01
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272 · University of PennsylvaniaDulaglutidePhase 2Recruiting302021-07-16
Comparison of Type 2 Diabetes Pharmacotherapy RegimensNCT05073692 · Kaiser PermanenteExenatide—Completed2419812021-07-01
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 · Eli Lilly and CompanyRetatrutidePhase 1Completed642021-05-24
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 · Eli Lilly and CompanyRetatrutidePhase 2Completed3382021-05-20
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · Eli Lilly and CompanyRetatrutidePhase 2Completed2812021-05-13
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181 · Novo Nordisk A/SSemaglutidePhase 3Active not recruiting●Now tracking12052021-04-01
Peri-implant Vitamin D and Cathelicidin (LL-37) LevelsNCT06867250 · Altinbas UniversityLL-37—Completed332021-04-01
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082 · Novo Nordisk A/SLiraglutidePhase 3Active not recruiting782021-03-04
Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV PeriodontitisNCT04861493 · Cairo UniversityLL-37—Completed602021-02-23
Brain Activation and Satiety in Children 2NCT04520490 · Seattle Children's HospitalExenatidePhase 3Active not recruiting632021-01-28
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionNCT05485818 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Completed622020-11-23
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844 · University of VirginiaLiraglutidePhase 4Recruiting802020-11-01
Exenatide Once-weekly as a Treatment for Multiple System AtrophyNCT04431713 · University College, LondonExenatidePhase 2Completed502020-09-16
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · Eli Lilly and CompanyDulaglutidePhase 3Completed132992020-05-29
A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNCT04154072 · Neuraly, Inc.ExenatidePhase 2Completed2552020-02-27
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969 · University College, LondonExenatidePhase 3Completed1942020-01-20
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 · Eli Lilly and CompanyRetatrutidePhase 1Completed722019-12-18
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionNCT01311518 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Withdrawn02019-07
A Study of LY3502970 in Healthy ParticipantsNCT03929744 · Eli Lilly and CompanyOrforglipronPhase 1Completed1332019-06-12
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3NCT03937882 · ReGenTree, LLCThymosin Beta-4Phase 3Completed●Results posted7002019-05-24
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561 · Novo Nordisk A/SSemaglutidePhase 3Active not recruiting●Now tracking15002019-05-08
Liraglutide Effect in Atrial FibrillationNCT03856632 · University of MiamiLiraglutidePhase 4Active not recruiting602019-03-18
A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 · Eli Lilly and CompanyRetatrutidePhase 1Completed452019-03-13
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412 · University of VirginiaLiraglutidePhase 4Recruiting●Now tracking602019-02-28
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related DiseaseNCT06725693 · Tianjin Medical UniversityExenatide—Recruiting5002019-02-01
Growth Hormone Dynamics and Cardiac Steatosis in HIVNCT03826160 · Massachusetts General HospitalTesamorelin—Completed232019-01-30
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskNCT03375788 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Completed512019-01-17
A Phase 1b Study of Thymosin Beta 4 in Healthy VolunteersNCT04555850 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 1Completed302018-07-30
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryNCT03150511 · Johns Hopkins UniversityTesamorelinPhase 2Recruiting362018-06-01
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001 · Centre Hospitalier Universitaire DijonLiraglutideDulaglutide—Completed422018-04-16
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseNCT03492580 · Janssen Research & Development, LLCDulaglutideExenatide—Completed7145822018-02-22
Body Composition and Adipose Tissue in HIVNCT03226821 · Columbia UniversityTesamorelinPhase 4Terminated62018-02-07
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their CombinationNCT03878706 · University of AthensLiraglutideMOTS-c—Recruiting2402017-11-03
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentNCT02553603 · The University of Texas Medical Branch, GalvestonSermorelinTesamorelinPhase 1Completed222017-07-18
A Phase 1a Study of Thymosin Beta 4 in Healthy VolunteersNCT04555824 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 1Completed542017-07-17
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsNCT02572323 · University of California, San DiegoTesamorelinPhase 2Completed732017-02-15
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyNCT02860923 · University Hospital, BordeauxExenatidePhase 3Completed422017-01-11
Study of Intranasal Octreotide (DP1038) in Healthy Adult VolunteersNCT03031535 · Dauntless PharmaceuticalsSermorelinPhase 1Completed322017-01
Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500 · Beth Israel Deaconess Medical CenterLiraglutidePhase 4Active not recruiting282016-11
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2NCT02974907 · ReGenTree, LLCThymosin Beta-4Phase 3Completed6012016-11
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaNCT02931474 · National Institute of Nursing Research (NINR)TesamorelinPhase 2Withdrawn02016-10-06
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.NCT02806414 · University of California, San DiegoLL-37Phase 1/Phase 2Completed252016-07
Pharmacogenomics of GLP1 Receptor AgonistsNCT05762744 · University of Maryland, BaltimoreExenatidePhase 1Terminated632016-06-01
Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian ResponseNCT02736591 · Cairo UniversitySermorelinPhase 3Unknown2102016-06
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsNCT02773355 · Novo Nordisk A/SLiraglutide—Completed272016-05-16
GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryNCT02673931 · Copenhagen University Hospital, RigshospitaletExenatide—Unknown●Status change14002016-02
Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.NCT02138591 · University of Missouri, Kansas CityLL-37Phase 3Withdrawn02016-02
Cohort Of DEafness-gene ScreeningNCT06133946 · Affiliated Hospital of Nantong UniversityMOTS-c—Active not recruiting359202016-01-01
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeNCT02251431 · Baylor Research InstituteExenatidePhase 3Completed572015-11
PCO-02 - Safety and Pharmacokinetics TrialNCT02637284 · PharmaCotherapia d.o.o.BPC-157Phase 1Unknown422015-10
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1NCT02597803 · ReGenTree, LLCThymosin Beta-4Phase 2/Phase 3Completed3172015-09
Tesamorelin Effects on Liver Fat and Histology in HIVNCT02196831 · Massachusetts General HospitalSermorelinTesamorelin—Completed612015-07-01
Estradiol-Receptor Blockade in Older Men and WomenNCT02271282 · Mayo ClinicSermorelinPhase 1Completed402014-12
Liver and Fat Regulation in Overweight Adolescent GirlsNCT02157974 · University of Colorado, DenverExenatidePhase 2/Phase 3Completed922014-08
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesNCT02674893 · Centre Hospitalier Universitaire DijonLiraglutidePhase 4Terminated482014-02-04
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CADNCT04027712 · University of AthensMOTS-c—Unknown1202014-01-01
Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)NCT02507245 · Stefania La Grutta, MDSermorelin—Completed482014-01
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone AnalogueNCT01632592 · Massachusetts General HospitalSermorelinTesamorelin—Withdrawn02014-01
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood FlowNCT01988545 · Zealand University HospitalExenatide—Completed●Now tracking82013-11-01
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesNCT01794143 · GRADE Study GroupLiraglutidePhase 3Completed78502013-05
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®NCT01579695 · TheratechnologiesTesamorelin—Terminated3912013-02
Effects of Transcranial Magnetic Stimulation on Object RecognitionNCT01747200 · National Institute of Neurological Disorders and Stroke (NINDS)Selank—Completed132012-11-16
Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismNCT02721888 · Centre Hospitalier Universitaire DijonLiraglutidePhase 4Terminated1272012-07-10
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®NCT01591902 · TheratechnologiesTesamorelinPhase 4Terminated1292012-06
Egrifta Replacement and Sleep Disordered BreathingNCT01788462 · Johns Hopkins UniversityTesamorelin—Withdrawn02012-05
Effects of Smoking and Vitamin D3 on the Levels of Human Cathelicidin Peptide LL-37NCT03923218 · Gazi UniversityLL-37—Completed602011-12
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingNCT01388920 · TheratechnologiesTesamorelinPhase 2Terminated32011-09
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeNCT01387347 · ReGenTree, LLCThymosin Beta-4Phase 2Completed722011-08
Effects of Aminocaproic Acid (ACA) on Rosacea-specific InflammationNCT01398280 · University of California, San DiegoLL-37EARLY_Phase 1Completed152011-07
Vitamin D in Ventilated ICU PatientsNCT01372995 · Emory UniversityLL-37Phase 2Completed312011-07
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT01410799 · University of PennsylvaniaSermorelinPhase 2Terminated132011-05
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionNCT01280344 · Helsinn Therapeutics (U.S.), IncIpamorelinPhase 2Completed3202011-04
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry EyeNCT01393132 · Michigan Cornea Consultants, PCThymosin Beta-4Phase 2Completed92011-03
VRS-317 in Adult Subjects With Growth Hormone DeficiencyNCT01359488 · Versartis Inc.SermorelinPhase 1Completed502011-03
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese DiabeticsNCT02042664 · Assistance Publique Hopitaux De MarseilleExenatidePhase 3Completed442011-01
Effects of Growth Hormone Releasing Hormone in HIVNCT01263717 · Massachusetts General HospitalSermorelinTesamorelin—Completed542010-12
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsNCT01343641 · University of VirginiaMK-677Phase 2Withdrawn02009-03
Effects of Short-term Growth Hormone in HIV-infected PatientsNCT00795210 · Massachusetts General HospitalSermorelinTesamorelin—Completed252009-02
Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenNCT00850564 · Massachusetts General HospitalSermorelinTesamorelin—Completed152009-02
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMNCT01107717 · The University of Texas Health Science Center at San AntonioExenatidePhase 4Completed3182009-01
Vitamin D in Active Tuberculosis (TB) StudyNCT00788320 · Atlanta VA Medical CenterLL-37—Withdrawn02008-10
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are ObeseNCT00675506 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Completed602008-07
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive PatientsNCT02012556 · TheratechnologiesSermorelinTesamorelinPhase 1Completed182008-05
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersNCT00743769 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 1Withdrawn02008-04
Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusNCT00672074 · Helsinn Therapeutics (U.S.), IncIpamorelinPhase 2Completed1172008-04
Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT00807365 · Johns Hopkins UniversitySermorelinPhase 2Terminated52007-12-17
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal WoundsNCT00598871 · ReGenTree, LLCThymosin Beta-4Phase 2Terminated122007-12
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolNCT00679042 · CellTrans Inc.ExenatidePhase 3Active not recruiting212007-09-05
TH9507 Extension Study in Patients With HIV-Associated LipodystrophyNCT00608023 · TheratechnologiesSermorelinTesamorelinPhase 3Completed2632007-08
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone TestingNCT00324064 · Children's Mercy Hospital Kansas CitySermorelin—Completed902007-07
Adult Growth Hormone Deficiency and Cardiovascular RiskNCT00720902 · Columbia UniversitySermorelinPhase 4Terminated72007-02
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationNCT07677865 · West China HospitalLiraglutide—Completed2138912007-01-01
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD PatientsNCT00395291 · University of VirginiaMK-677—Completed492006-08
Study of Thymosin Beta 4 in Patients With Venous Stasis UlcersNCT00832091 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Completed722006-07
Study of Thymosin Beta 4 in Patients With Pressure UlcersNCT00382174 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Completed722006-05
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis BullosaNCT00311766 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Terminated302006-02
SMART: Somatotrophics, Memory, and Aging Research TrialNCT00257712 · University of WashingtonSermorelinTesamorelinPhase 2Completed1512006-02
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527 · ConjuChemCJC-1295Phase 2Terminated1202005-12
Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)NCT00128115 · Merck Sharp & Dohme LLCMK-677Phase 2Terminated832005-09
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of FibromyalgiaNCT00116129 · Bennett, Robert, M.D.MK-677Phase 2Completed642005-07
TH9507 in Patients With HIV-Associated LipodystrophyNCT00123253 · TheratechnologiesSermorelinTesamorelinPhase 3Completed4122005-06
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart FailureNCT00791843 · University of PennsylvaniaSermorelinPhase 2Completed32004-03
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone DeficiencyNCT01060488 · Merck KGaA, Darmstadt, GermanySermorelinPhase 3Completed692004-01
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)NCT00074529 · Merck Sharp & Dohme LLCMK-677Phase 2Completed5122003-10
Safety Study of TH9507 in Subjects With Stable, Type 2 DiabetesNCT01264497 · TheratechnologiesTesamorelinPhase 2Completed552002-02
Diagnosing Adult Growth Hormone DeficiencyNCT03018886 · Helsinki University Central HospitalSermorelin—Completed1602001-05
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsNCT00474279 · University of VirginiaMK-677Phase 1/Phase 2Completed721998-07
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep DisturbancesNCT00000380 · University of WashingtonSermorelin—Completed—1996-06
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in AcromegalyNCT00004332 · National Center for Research Resources (NCRR)Sermorelin—Completed1481993-05
Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401 · Eli Lilly and CompanyRetatrutide—Available——

Trial data sourced from ClinicalTrials.gov(U.S. National Library of Medicine), a public-domain registry. Synptide adds the compound tagging and grouping. Registry data can lag real-world status — always confirm on the source record before relying on it.